Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Article
PubMed
Google Scholar
Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30(6):644–6. https://doi.org/10.1200/JCO.2011.39.1300.
Article
CAS
PubMed
Google Scholar
Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75(1):88–99. https://doi.org/10.1016/j.eururo.2018.03.028.
Article
PubMed
Google Scholar
Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, Palleschi M, et al. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Crit Rev Oncol Hematol. 2021;157:103199. https://doi.org/10.1016/j.critrevonc.2020.103199.
Article
PubMed
Google Scholar
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. https://doi.org/10.1056/NEJMoa040720.
Article
CAS
PubMed
Google Scholar
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376:1147–54.
Article
Google Scholar
Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014;65(6):1198–204. https://doi.org/10.1016/j.eururo.2013.07.022.
Article
CAS
PubMed
Google Scholar
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582–91. https://doi.org/10.1001/jamaoncol.2015.1341.
Article
PubMed
PubMed Central
Google Scholar
Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, et al. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;116:158–68. https://doi.org/10.1016/j.ejca.2019.05.007.
Article
CAS
PubMed
Google Scholar
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59. https://doi.org/10.1200/JCO.2007.12.4487.
Article
PubMed
Google Scholar
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–7. https://doi.org/10.1200/JCO.1999.17.11.3461.
Article
CAS
PubMed
Google Scholar
Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10.
Article
PubMed
PubMed Central
Google Scholar
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444–57. https://doi.org/10.1158/2159-8290.CD-17-0937.
Article
CAS
PubMed
Google Scholar
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(7):1508–16. https://doi.org/10.1093/annonc/mdx155.
Article
CAS
Google Scholar
Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, et al. Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer. Mol Cancer Res. 2021;19(6):1040–50.
Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014;11(3):129–44. https://doi.org/10.1038/nrclinonc.2013.253.
Article
CAS
PubMed
Google Scholar
Chang P-H, Chen M-C, Tsai Y-P, Tan GYT, Hsu P-H, Jeng Y-M, et al. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proc Natl Acad Sci U S A. 2021;118(3):e2014408118. https://doi.org/10.1073/pnas.2014408118.
Article
CAS
PubMed
PubMed Central
Google Scholar
Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015;16(10):1521–37. https://doi.org/10.1517/14656566.2015.1055249.
Article
CAS
PubMed
PubMed Central
Google Scholar
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–11. https://doi.org/10.1038/nrc4016.
Article
CAS
PubMed
PubMed Central
Google Scholar
Usher JL, Athreya K, Ishiba T, Samberg D, Vodala S, Dang M, et al. Detection of AR-V7 using cell-free RNA (cfRNA) in prostate cancer. J Clin Oncol. 2016;34(15_suppl):e16613. https://doi.org/10.1200/JCO.2016.34.15_suppl.e16613.
Article
Google Scholar
Kölbl AC, Jeschke U, Andergassen U. The significance of epithelial-to-mesenchymal transition for circulating tumor cells. Int J Mol Sci. 2016;17(8). https://doi.org/10.3390/ijms17081308.
Pereira-Veiga T, González-Conde M, León-Mateos L, Piñeiro-Cid R, Abuín C, Muinelo-Romay L, et al. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. Clin Exp Metastasis. 2021;38(2):239–51. https://doi.org/10.1007/s10585-021-10075-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013;45(12):2736–48. https://doi.org/10.1016/j.biocel.2013.09.008.
Article
CAS
PubMed
Google Scholar
Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77(1):74–85. https://doi.org/10.1158/0008-5472.CAN-16-1656.
Article
CAS
PubMed
Google Scholar
Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5(3):280–5. https://doi.org/10.1038/6495.
Article
CAS
PubMed
Google Scholar
Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101(12):1949–56. https://doi.org/10.1038/sj.bjc.6605376.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget. 2016;7(27):41677–90. https://doi.org/10.18632/oncotarget.9528.
Article
PubMed
PubMed Central
Google Scholar
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–38. https://doi.org/10.1056/NEJMoa1315815.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72(23):6142–52. https://doi.org/10.1158/0008-5472.CAN-12-1335.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cho H, Il Chung J, Kim J, Seo WI, Lee CH, Morgan TM, et al. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. Cancer Sci. 2021;112(2):859–70. https://doi.org/10.1111/cas.14745.
Article
CAS
PubMed
Google Scholar
Josefsson A, Larsson K, Månsson M, Björkman J, Rohlova E, Åhs D, et al. Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. Oncotarget. 2018;9(50):29403–13. https://doi.org/10.18632/oncotarget.25634.
Article
PubMed
PubMed Central
Google Scholar
Lampignano R, Schneck H, Neumann M, Fehm T, Neubauer H. Enrichment, isolation and molecular characterization of EpCAM-negative circulating tumor cells. Adv Exp Med Biol. 2017;994:181–203. https://doi.org/10.1007/978-3-319-55947-6_10.
Article
CAS
PubMed
Google Scholar
de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget. 2018;9(86):35705–16. https://doi.org/10.18632/oncotarget.26298.
Article
PubMed
PubMed Central
Google Scholar
Bredemeier M, Edimiris P, Mach P, Kubista M, Sjöback R, Rohlova E, et al. Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer. Clin Chem. 2017;63(10):1585–93. https://doi.org/10.1373/clinchem.2016.269605.
Article
CAS
PubMed
Google Scholar
Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O’Neill KL. Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies. Mol Cell Oncol. 2019;6(2):1575691–10. https://doi.org/10.1080/23723556.2019.1575691.
Article
CAS
PubMed
PubMed Central
Google Scholar
Townsend MH, Bennion KB, Bitter EE, Felsted AM, Robison RA, O’Neill KL. Overexpression and surface localization of HPRT in prostate cancer provides a potential target for cancer specific antibody mediated cellular cytotoxicity. Exp Cell Res. 2021;403(1):112567. https://doi.org/10.1016/j.yexcr.2021.112567.
Article
CAS
PubMed
Google Scholar
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16–22. https://doi.org/10.1158/0008-5472.CAN-08-2764.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715–30. https://doi.org/10.1172/JCI41824.
Article
CAS
PubMed
PubMed Central
Google Scholar
Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun. 2016;7(1):13668. https://doi.org/10.1038/ncomms13668.
Article
CAS
PubMed
PubMed Central
Google Scholar
Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJM, Mathijssen RHJ, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. 2015;68(6):939–45. https://doi.org/10.1016/j.eururo.2015.07.007.
Article
CAS
PubMed
Google Scholar
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, et al. AR-V7 and prostate cancer: the watershed for treatment selection? Cancer Treat Rev. 2016;43:27–35. https://doi.org/10.1016/j.ctrv.2015.12.003.
Article
CAS
PubMed
Google Scholar
Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270–82. https://doi.org/10.1158/0008-5472.CAN-13-2876.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, et al. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget. 2015;6(27):23358–71. https://doi.org/10.18632/oncotarget.4396.
Article
PubMed
PubMed Central
Google Scholar
Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(9):1859–65. https://doi.org/10.1093/annonc/mdv282.
Article
CAS
Google Scholar
Taplin M-E, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, et al. Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(6):843–51. https://doi.org/10.1016/j.eururo.2019.08.034.
Article
CAS
PubMed
Google Scholar
Eisenberger M, Hardy-Bessard A-C, Kim CS, Géczi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198–206. https://doi.org/10.1200/JCO.2016.72.1076.
Article
CAS
PubMed
Google Scholar
Shen Y, Gao Y, Yuan H, Cao J, Jia B, Li M, et al. Prohibitin-2 negatively regulates AKT2 expression to promote prostate cancer cell migration. Int J Mol Med. 2018;41(2):1147–55. https://doi.org/10.3892/ijmm.2017.3307.
Article
CAS
PubMed
Google Scholar
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9. https://doi.org/10.1158/1078-0432.CCR-08-0872.
Article
CAS
PubMed
Google Scholar